Related Experiment Videos
Characterization and immunomodulating activities of polysaccharide from Lentinus edodes
Ruan Zheng1, Su Jie, Dai Hanchuan
1Laboratory of Functional Food and Nutrition, College of Food Science and Technology, Huazhong Agricultural University, Wuhan 430070, PR China.
International Immunopharmacology
|March 22, 2005
Summary
This study shows that polysaccharide L-II from Lentinus edodes enhances immune responses in mice with sarcoma 180. It boosts T-cell and macrophage activity, reducing tumor growth and increasing survival.
Area of Science:
- Immunology
- Pharmacology
- Biochemistry
Background:
- The fruiting body of Lentinus edodes contains bioactive polysaccharides.
- Polysaccharides are known for their immunomodulatory and potential antitumor properties.
Purpose of the Study:
- To investigate the immunomodulatory and antitumor effects of polysaccharide L-II isolated from Lentinus edodes.
- To evaluate the impact of polysaccharide L-II on cellular immunity in a murine model of Sarcoma 180.
Main Methods:
- Isolation and purification of polysaccharide L-II from Lentinus edodes.
- Administration of polysaccharide L-II to Sarcoma 180-bearing mice at varying doses (1, 5, 10 mg/kg).
- Assessment of tumor weight, immune organ indices, DTH response, macrophage phagocytosis, splenocyte proliferation, and serum cytokine levels (TNF-α, IFN-γ, IL-2).
Main Results:
- Polysaccharide L-II significantly reduced tumor weight and increased spleen and thymus indices.
- Enhanced delayed-type hypersensitivity (DTH) response and macrophage phagocytic activity were observed.
- Increased serum levels of tumor necrosis factor-alpha (TNF-α) and interferon-gamma (IFN-γ) were noted, along with elevated NO production and catalase activity in macrophages.
Conclusions:
- Polysaccharide L-II exhibits significant antitumor activity against Sarcoma 180 in mice.
- The antitumor effect is mediated by immunomodulation, involving the enhancement of T-cell and macrophage-dependent immune responses.
- Lentinus edodes-derived polysaccharide L-II shows promise as an immunotherapeutic agent.